Muriel D. Brada

Muriel D. Brada

Auto-generated profile, based on publicly available information

Muriel D. Brada

Department of Pathology and Molecular Pathology, University Hospital Zürich, Zürich, Switzerland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Neoplasia
Verified
Journal Article
Open access
SFSandra N. Freiberger
Sandra N. Freiberger
MBMuriel Brada
Muriel Brada
CFChristine Fritz
Christine Fritz
SHSylvia Höller
Sylvia Höller
AVAlexander Vogetseder
Alexander Vogetseder
NRNiels J. Rupp
Niels J. Rupp
Diagnosis of salivary gland neoplasms is often challenging due to their high morphological diversity and overlaps. Several recurrent molecular alterations have been described recently, which can serve as powerful diagnostic tools and potential therapeutic targets (e.g. NTRK or RET fusions). However, current sequential molecular testing can be expensive and time consuming. In order to facilitate the diagnosis of salivary gland neoplasms, we designed an all-in-one RNA-based next generation sequencing panel suitable for the detection of mutations, fusions and gene expression levels (including NR4A3) of 27 genes involved in salivary gland neoplasms. Here we present the validation of the "SalvGlandDx" panel on FFPE histological specimen including fine needle aspiration (FNA) cell block material, against the standard methods currently used at our institution. In a second part we describe selected unique cases in which the SalvGlandDx panel allowed proper diagnosis and new insights into special molecular characteristics of selected salivary gland tumors. We characterize a unique salivary gland adenocarcinoma harboring a ZCCHC7-NTRK2 fusion, a highly uncommon spindle cell and pseudoangiomatoid adenoid-cystic carcinoma with MYBL1-NFIB fusion, and a purely oncocytic mucoepidermoid carcinoma, whereas diagnosis could be made by detection of a CRTC3-MAML2 rearrangement on the cell block specimen of the FNA. Further, a rare case of a SS18-ZBTB7A rearranged low-grade adenocarcinoma previously described as potential spectrum of microsecretory adenocarcinoma, is reported. In addition, features of six cases within the spectrum of polymorphous adenocarcinoma / cribriform adenocarcinoma of salivary gland including PRKD1 p.E710D mutations and novel fusions involving PRKAR2A-PRKD1, SNX9-PRKD1 and ATL2-PRKD3, are described.

28 February 2022 in Journal of Perinatology
Verified
Journal Article
Open access
PDF file
LHLia Hellwig
Lia Hellwig
MBMuriel Brada
Muriel Brada
UHUlrike Held
Ulrike Held
CHCornelia Hagmann
Cornelia Hagmann
PBPeter Bode
Peter Bode
BGBeate Grass
Beate Grass
Objective: Placental pathology might provide information on the etiology of hypoxic-ischemic encephalopathy (HIE). To evaluate the association of perinatal sentinel events (PSE), placental pathology and cerebral MRI in cooled neonates with moderate/severe HIE.Study design: Retrospective analysis of 52 neonates with HIE registered in the Swiss National Asphyxia and Cooling Register 2011–2019. PSE and Non-PSE groups were tested for association with placental pathology. Placental pathology categories were correlated with MRI scores.Results: In total, 14/52 neonates (27%) had a PSE, 38 neonates (73%) did not have a PSE. There was no evidence for an association of occurrence of PSE and placental pathologies (p = 0.364). Neonates with high MRI scores tended to have more often chronic pathologies in their placentas than acute pathologies or normal placentas (p = 0.067).Conclusion: Independent of the occurrence of PSE, chronic placental pathologies might be associated with more severe brain injury and needs further study.

23 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
NANagjie Alijaj
Nagjie Alijaj
BPBlaz Pavlovic
Blaz Pavlovic
PMPaul Martel
Paul Martel
ARArnas Rakauskas
Arnas Rakauskas
VCValérie Cesson
Valérie Cesson
DEDaniel Eberli
Daniel Eberli
PCa screening is based on the measurements of the serum prostate specific antigen (PSA) to select men with higher risks for tumors and, thus, eligible for prostate biopsy. However, PSA testing has a low specificity, leading to unnecessary biopsies in 50–75% of cases. Therefore, more specific screening opportunities are needed to reduce the number of biopsies performed on healthy men and patients with indolent tumors. Urine samples from 45 patients with elevated PSA were collected prior to prostate biopsy, a mass spectrometry (MS) screening was performed to identify novel biomarkers and the best candidates were validated by ELISA. The urine quantification of PEDF, HPX, CD99, CANX, FCER2, HRNR, and KRT13 showed superior performance compared to PSA. Additionally, the combination of two biomarkers and patient age resulted in an AUC of 0.8196 (PSA = 0.6020) and 0.7801 (PSA = 0.5690) in detecting healthy men and high-grade PCa, respectively. In this study, we identified and validated novel urine biomarkers for the screening of PCa, showing that an upfront urine test, based on quantitative biomarkers and patient age, is a feasible method to reduce the number of unnecessary prostate biopsies and detect both healthy men and clinically significant PCa.

22 April 2025 in The Journal of Pathology: Clinical Research
Verified
Journal Article
Open access
MBMuriel D Brada
Muriel D Brada
TKTülay Karakulak
Tülay Karakulak
PSPeter Schraml
Peter Schraml
MHMartina Haberecker
Martina Haberecker
DRDorothea Rutishauser
Dorothea Rutishauser
HMHolger Moch
Holger Moch
Novel treatment options for metastatic renal cell carcinomas (RCC) include specific MET inhibitors, GAS6/AXL inhibitors, and SRC inhibitors. The interplay between c‐MET, SRC, AXL expression, and their gene mutation patterns in different renal carcinoma subtypes is unclear. To improve the understanding of these signaling pathways, we analyzed c‐MET, AXL, and SRC expression in 590 clear cell RCC (ccRCC) and 127 papillary RCC (pRCC) by immunohistochemistry and integrated sequencing data to investigate the frequency of MET, AXL, and SRC gene mutations, their expression levels, and the presence of splice variants. In TCGA and in Foundation Medicine, Inc. (FMI) datasets, AXL and SRC gene alterations were extremely rare (<2%) or absent in ccRCC (n = 531 and 2,781, respectively) and pRCC (n = 290 and 566, respectively). On the other hand, MET mutations or amplifications were found in 9.7% (TCGA) and 10.2% (FMI) of pRCC. We show that strong SRC staining intensity by immunohistochemistry is associated with high tumor stage, high grade, and shorter survival in ccRCC (p < 0.001 each). AXL expression correlates with high stage and grade in ccRCC (p < 0.001 each). Both SRC and AXL expression were independent prognostic parameters in multivariate analysis (p < 0.05). MET expression is associated with longer survival in pRCC (p < 0.05). Our TCGA data analysis aligns with SRC immunohistochemistry findings on tumor stage and shorter survival in ccRCC. TCGA expression data showed a moderate positive correlation between AXL and c‐MET in pRCC. In addition, we identified alternative splicing events reported for AXL in pRCC, and MET and SRC in ccRCC, across various alternative splicing databases. In conclusion, we identified high SRC expression as a biomarker for poor prognosis of ccRCC. Our data demonstrate c‐MET, AXL, and SRC signaling pathway interactions independent of c‐MET, AXL, and SRC mutations in ccRCC.

11 May 2022 in Head and Neck Pathology
Verified
Journal Article
Open access
PDF file
MBMuriel D. Brada
Muriel D. Brada
ERElisabeth J. Rushing
Elisabeth J. Rushing
DBDavid Bächinger
David Bächinger
LZLoris Zoller
Loris Zoller
IBIrene A. Burger
Irene A. Burger
NRNiels J. Rupp
Niels J. Rupp
Background: Endolymphatic sac tumors are rare neoplasia characterized by slow growth. However, their clinical impact should not be underestimated, considering their potential for local aggressive behavior and strong association with von Hippel–Lindau syndrome. Therefore, early detection with emerging theragnostic examinations such as 68Ga-DOTATATE-PET/CT might improve patient management and reduce morbidity. Methods: We report the clinicopathological features of seven endolymphatic sac tumors. In this cohort, we performed immunohistochemical analysis of somatostatin receptor 2A (SSTR2A) and prostate specific membrane antigen (PSMA) protein expression patterns; two targets providing rationale for novel imaging modalities such as PSMA- or SSTR-targeted PET. Results: The tumor cells of all cases were negative for prostate specific membrane antigen and somatostatin receptor 2A, however immunolabeling was consistently detected in intratumoral endothelial cells of endolymphatic sac tumors for PSMA (7/7 cases, 100%), and for SSTR2A (5/7 cases, 71%). Conclusions: Our results show a high rate of PSMA and SSTR2A expression in the tumor vasculature of endolymphatic sac tumors. PSMA and SSTR2A can be targeted with appropriate radioligands for diagnostic and therapeutic purposes. This finding provides a rationale for prospective clinical studies to test this approach as a sensitive screening tool for patients with suspected endolymphatic sac tumors including an improved management of von Hippel–Lindau syndrome.

2 September 2026 in Head & Neck
Verified
Journal Article
Open access
PDF file
MMMichael A. Müller
Michael A. Müller
MBMuriel D. Brada
Muriel D. Brada
NRNiels J. Rupp
Niels J. Rupp
CRCosima E. Riemenschnitter
Cosima E. Riemenschnitter
SMSimon Müller
Simon Müller
GMGrégoire B. Morand
Grégoire B. Morand
Background: Perineural invasion (PNI) is an established adverse prognostic factor in oral squamous cell carcinoma (OSCC), but the implications of its extent as well as its relationship with surgical margin status and the extent of microscopic tumor spread remain unclear. Methods: We retrospectively analyzed 165 patients with OSCC treated surgically with curative intent between 2010 and 2019. PNI was assessed for presence, subtype, number of foci, location, and diameter of the largest involved nerve. Associations with margin status and survival outcomes were evaluated using univariate and multivariate analyses. Results: PNI was present in 29 patients (17.6%) and was associated with advanced tumor stage, nodal metastasis, positive surgical margins (HR 3.4, 95% CI 1.1–10.2), and increased use of adjuvant radiotherapy. While PNI presence predicted poorer survival, the diameter of the largest invaded nerve provided superior prognostic discrimination. A cutoff of 200 μm independently predicted disease‐specific survival (HR 5.7, 95% CI 1.7–19.0) and significantly improved multivariable model performance. Conclusions: PNI correlates with positive surgical margins. Quantifying PNI, particularly nerve diameter, enhances prognostic stratification and may inform individualized surgical margin planning in OSCC.